Want to see OLMA full AI Analyst Report?
Top Page
Olema Pharmaceuticals
(NASDAQ:OLMA)
Select Model
Select Model
Rating:45Neutral
Price Target:
$10.50
▼(-3.76% Downside)
Action:Reiterated
Date:08/17/26
The score is held down primarily by weak financial performance (no revenue, widening losses, and heavy cash burn) and bearish-to-weak technicals (price below key moving averages with negative MACD). A strong, low-debt balance sheet partially offsets these risks, while valuation metrics (negative P/E and no dividend yield provided) offer limited support.
Positive Factors
Very low leverage and balance-sheet flexibility
Minimal debt gives Olema financial flexibility while it funds clinical development. The $486.6M asset base provides support for ongoing operations, although continued losses could reduce this cushion over time.
Negative Factors
No product revenue or commercial traction
Olema remains entirely dependent on clinical success because it has no approved products or recurring commercial revenue. This leaves the company without an operating revenue base to absorb research, development, and corporate expenses.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage and balance-sheet flexibility
Minimal debt gives Olema financial flexibility while it funds clinical development. The $486.6M asset base provides support for ongoing operations, although continued losses could reduce this cushion over time.
Read all positive factors
Olema Pharmaceuticals (OLMA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$954.60M
Dividend YieldN/A
Average Volume (3M)1.59M
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue GrowthN/A
EPS Growth-10.16%
CountryUS
Employees150
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.12
Shares Outstanding87,497,604
10 Day Avg. Volume930,349
30 Day Avg. Volume1,592,633
Financial Highlights & Ratios
PEG Ratio0.89
Price to Book (P/B)4.55
Price to Sales (P/S)0.00
P/FCF Ratio-14.83
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$38.13Price Target Upside249.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.38
Revenue Forecast (FY)$2.25M
Olema Pharmaceuticals Business Overview & Revenue Model
Company Description
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the ...
How the Company Makes Money
Olema does not sell approved products; as a clinical-stage biotechnology company, it has not historically generated product revenue and primarily funds operations through financing activities (e.g., issuing equity and related capital-raising trans...
Olema Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -306.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -204.00M | -161.96M | -129.08M | -96.28M | -104.43M | -70.93M |
| Net Income | -204.57M | -162.45M | -129.47M | -96.66M | -104.79M | -71.10M |
Balance Sheet | ||||||
| Total Assets | 486.58M | 533.43M | 450.98M | 276.94M | 215.65M | 295.94M |
| Cash, Cash Equivalents and Short-Term Investments | 461.07M | 505.44M | 434.09M | 261.81M | 204.42M | 287.25M |
| Total Debt | 660.00K | 1.19M | 1.43M | 2.42M | 2.56M | 3.29M |
| Total Liabilities | 56.01M | 54.87M | 42.02M | 23.05M | 18.10M | 11.38M |
| Stockholders Equity | 430.56M | 478.56M | 408.96M | 253.90M | 197.55M | 284.57M |
Cash Flow | ||||||
| Free Cash Flow | -164.74M | -146.72M | -104.51M | -83.73M | -82.43M | -52.27M |
| Operating Cash Flow | -164.74M | -146.72M | -104.35M | -83.73M | -82.06M | -50.69M |
| Investing Cash Flow | -99.54M | -155.76M | -93.53M | -4.85M | 91.48M | -275.44M |
| Financing Cash Flow | 260.40M | 211.30M | 268.82M | 133.41M | 476.00K | 1.39M |
Olema Pharmaceuticals Technical Analysis
Negative
10.91
Price Trends
11.34
Negative
12.60
Negative
17.66
Negative
Market Momentum
-0.23
Positive
46.39
Neutral
42.06
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OLMA, the sentiment is Negative. The current price of 10.91 is below the 20-day moving average (MA) of 11.11, below the 50-day MA of 11.34, and below the 200-day MA of 17.66, indicating a bearish trend. The MACD of -0.23 indicates Positive momentum. The RSI at 46.39 is Neutral, neither overbought nor oversold. The STOCH value of 42.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OLMA.
Olema Pharmaceuticals Risk Analysis
Olema Pharmaceuticals disclosed 92 risk factors in its most recent earnings report. Olema Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Olema Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $1.43B | 19.16 | 284.38% | ― | 948.35% | ― | |
63 Neutral | $627.71M | 49.05 | 1.91% | ― | -15.05% | ― | |
54 Neutral | $99.97M | -0.31 | 108.75% | ― | 32.43% | 7.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $231.58M | -3.01 | -21.40% | ― | -93.55% | -1143.58% | |
45 Neutral | $954.60M | -5.12 | -48.22% | ― | ― | -10.16% | |
45 Neutral | $455.62M | -5.86 | -38.71% | ― | ― | 10.44% |
* Healthcare Sector Average
OLMA
Olema Pharmaceuticals
10.85
5.33
96.56%
MGTX
Meiragtx Holdings
14.56
7.07
94.39%
ARVN
Arvinas Holding Company
9.32
1.56
20.10%
GOSS
Gossamer Bio
0.17
-2.23
-92.79%
KROS
Keros Therapeutics
11.12
-4.13
-27.08%
CMPX
Compass Therapeutics
2.43
-1.06
-30.37%
Olema Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board Changes
Olema Pharmaceuticals Names New Chief Financial Officer
Positive
Aug 13, 2026
On August 13, 2026, Olema Pharmaceuticals announced that it had appointed veteran biotech finance executive Jason O’Byrne as chief financial officer, effective August 11, 2026, with the board’s approval granted on July 28, 2026. The cl...
Executive/Board ChangesShareholder Meetings
Olema Investors Back Board, Pay and Auditor Decisions
Positive
Jun 23, 2026
Olema Pharmaceuticals held its annual meeting of stockholders on June 17, 2026, where investors voted on board composition, executive pay and auditor selection. The company’s governance decisions at this meeting help shape its strategic dire...
Business Operations and StrategyProduct-Related Announcements
Olema, Bayer launch OP-3136 prostate cancer collaboration
Positive
May 26, 2026
On May 26, 2026, Olema Oncology announced a clinical trial collaboration and supply agreement with Bayer to test its investigational KAT6 inhibitor OP-3136 in combination with Bayer’s androgen receptor inhibitor Nubeqa (darolutamide) in meta...
Business Operations and StrategyProduct-Related Announcements
Olema Highlights Encouraging OP-3136 Phase 1 Oncology Results
Positive
May 21, 2026
On May 21, 2026, Olema Oncology reported preliminary Phase 1 data for OP-3136, an oral KAT6 inhibitor, in heavily pretreated patients with ER+/HER2- advanced breast cancer, metastatic castration-resistant prostate cancer, and metastatic non-small ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.